Potent, cell permeable inhibitor of CaM kinase II (IC50
= 0.37 μ
M). Also a direct extracellular open channel blocker of voltage-gated potassium channels (IC50
= 307 nM for KV
1.5) and abolishes IKr in ventricular myocytes (IC50
= 102.6 nM) independently of CaM kinase II inhibition. Water soluble form
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Other Product-Specific Information:
Calcium/calmodulin-dependent phosphorylation and activation of human Cdc25-C at the G2/M phase transition in HeLa cells.
Patel et al.
KN-93 (2-[N-(2-Hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]-amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated
Rezazadeh et al.
The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine content in PC12h cells.
Sumi et al.
KN-93 inhibits IKr in mammalian cardiomyocytes.
Hegyi et al.
The citations listed below are publications that use Tocris products. Selected citations for KN 93 include:
Showing Results 1 - 10 of 17